Q-omics provides the consensus-scored TAS2R38 profile across patient tissues and cancer cell-line models. TAS2R38 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TAS2R38 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TAS2R38 RNA expression shows 13,959 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, COAD, and THYM as cancer lineages where TAS2R38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAS2R38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAS2R38 survival associations across molecular data types. TAS2R38 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAS2R38 RNA expression–survival associations across cancer types. High TAS2R38 expression shows unfavorable associations in LIHC, CHOL, UCEC, BRCA and COAD, but favorable associations in SCLC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TAS2R38 RNA expression.
This table summarizes TAS2R38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TAS2R38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAS2R38 shows higher tumor expression in COAD, HNSC, BLCA, LUSC, STAD and ESCA. The COAD box plot shows higher TAS2R38 RNA expression in tumor versus normal tissue (log2 FC = +0.905, t-test p < 0.001).
This table shows molecular features associated with TAS2R38 in patient tissues and cancer cell lines. In patient samples, TAS2R38 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAS2R38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
